What type of study is this?

This is a Validation Study study.

December 8, 2025BloodOpen Access

Evaluating the efficacy and safety of gene therapy in transfusion-dependent β-thalassemia: A focus on hemolysis improvement and clonal hematopoiesis monitoring

View Full Paper

Ask AI

Bookmark

Authors

FBFlorence Beckerich AHAnoosha Habibi

Discussion

Member takes

Overview

Observational analysis shows significant hemolysis improvement in transfusion-dependent β-thalassemia patients using gene therapy, indicating potential benefits despite clonal hematopoiesis concerns.

Key Points

Gene therapy resulted in substantial hemolysis improvement, with heme levels dropping by 98.5% from baseline.
Patient achieved transfusion independence with hemoglobin of 15.5 g/dL after gene editing, demonstrating effective treatment outcomes.
Assessment utilized CRISPR-Cas9 gene editing approach with real-world data from the first treated patient in France.
Long-term monitoring is essential due to detected low frequency of DNMT3A mutation, suggesting the need for continued vigilance against potential clonal expansion.

Cite This Study

Beckerich et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236dddc https://doi.org/10.1182/blood-2025-2914

View Full Paper

Ask AI

Bookmark

December 8, 2025BloodOpen Access

Evaluating the efficacy and safety of gene therapy in transfusion-dependent β-thalassemia: A focus on hemolysis improvement and clonal hematopoiesis monitoring

View Full Paper

Ask AI

Bookmark

Authors

FBFlorence Beckerich AHAnoosha Habibi

Discussion

Member takes

Overview

Key Points

Gene therapy resulted in substantial hemolysis improvement, with heme levels dropping by 98.5% from baseline.
Patient achieved transfusion independence with hemoglobin of 15.5 g/dL after gene editing, demonstrating effective treatment outcomes.
Assessment utilized CRISPR-Cas9 gene editing approach with real-world data from the first treated patient in France.
Long-term monitoring is essential due to detected low frequency of DNMT3A mutation, suggesting the need for continued vigilance against potential clonal expansion.

Cite This Study

Beckerich et al. (2025) studied this question.

synapsesocial.com/papers/69362f634fa91c937236dddc https://doi.org/10.1182/blood-2025-2914

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark